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Targeted therapyGrowing evidence indicates a cardio-pathogenic role of autoantibodies against β1-adrenergic receptors (β1AR).
In particular autoantibodies stimulating β1AR-mediated cAMP-production (i.e. agonistic β1AR autoantibodies)
play a paramount role in chronic heart failure. When induced by immunisation, such autoantibodies cause
heart failure in rodents; when present in patients they negatively affect survival in heart failure. However, the
true prevalence and clinical impact of agonistic β1AR autoantibodies in human heart disease are still unclear,
as are the events triggering their production, and the inter-relationship between autoantibody level and disease
activity. β1AR autoantibodies can be removed by extracorporeal absorption or neutralised by systemic adminis-
tration of synthetic epitope mimics. Only patients bearing agonistic β1AR autoantibodies in their bloodstream
will beneﬁt from these approaches. Therefore, reliable detection of agonistic β1AR autoantibodies is a key pre-
requisite for the future implementation of these strategies. β1AR autoantibodies impact on conformation and
down-stream signalling of the receptor by binding a conformational epitope,which is poorly represented by syn-
theticmimics and readily destroyed by ﬁxation. Consequently, β1AR autoantibodies can reliably be detected only
by assays utilising the nativeβ1AR as a test antigen. Toprovide a sufﬁcient basis for diagnostic predictions or ther-
apeutic decisions, onemust also determinewhether β1AR autoantibodies stimulate the receptor, which again re-
quires native, cell-based reporter systems. Translation of these procedures into versatile diagnostic tests ﬁtting
the requirements of general health care is a challenge for future development. Here, we will review the state
of diagnostic and therapeutic efforts in theﬁeld of β1AR-directed autoimmunity, thereby aiming to furnish a con-
ceptual frame for the further development of novel, more reliable diagnostic tools and more speciﬁc antibody-
targeted therapeutic concepts.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC-BY license
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Autoantibodies that bind to G-protein coupled receptors (GPCRs) of
neuro-endocrine transmitters have been demonstrated to possess the
potential to cause pathological changes in humans. These autoantibodies
alter base line activity and/or agonist responsiveness of the receptors and
thereby exert toxic effects in target tissues. It is suggested to classify such
clinical entities as GPCR-targeted agonistic autoantibody-diseases. The
most ﬁrmly established example is Grave's disease (M. Basedow), which
is caused by autoantibodies that stimulate the thyroid-stimulating hor-
mone receptor (TSH-R) and thereby promote pathologically enhanced
growth and endocrine dysfunction of the thyroid gland [1,2]. Over the
past three decades, growing evidence has accumulated that a number of
other aetiologies are probably based on the same pathogenic principle
and therefore should also be recognised as agonistic GPCR-targeted
autoantibody-diseases [3]. These aetiologies have in common (i) that
they are associated with circulating autoantibodies targeting GPCRs in-
volved in autonomic vegetative regulation, (ii) that these autoantibodies
mimic receptor agonists, and (iii) that the pathology predominantlyman-
ifests in the cardiovascular system and the kidney (Table 1; for a more
complete list please refer to [3]).
The β1-adrenergic receptor (β1AR) appears to be a common target
of several agonistic autoantibody-diseases that lead to chronic heart
failure (Table 1). Most notably, agonistic β1AR autoantibodies are in-
volved in the pathogenesis of dilated cardiomyopathy (DCM), a disease
characterised by progressive ventricular dilation and dysfunction due to
non-ischemic myocardial damage. A DCM sub-entity commonly classi-
ﬁed as “idiopathic” [4] is strongly associated with agonistic β1AR auto-
antibodies. The majority of idiopathic DCM patients have agonistic
β1AR autoantibodies in their circulation [5–7]. Clinical correlations
[6,8] in conjunction with animal immunisation experiments [9–14]
strongly suggest that these autoantibodies play a causal role in the
pathogenesis of the disease. Agonistic β1AR autoantibodies are also
present in roughly a third of ischemic cardiomyopathy cases [8,15],
and they are frequently associated with arrhythmic complications
also in other diseases primarily not affecting the heart [16]. It is estimatedTable 1
Established and emerging diseases caused by, or associated with, autoantibodies against G-pro
Disease/Syndrome Receptor type
Arterial hypertension (primary, malignant or refractory) α1-adrenergic
Pulmonary arterial hypertension α1-adrenergic
Preeclampsia angiotensin I
Renal allograft rejection angiotensin II
Dilated cardiomyopathy β1-adrenergic
β2-adrenergic
M2-muscarin
Chagas' disease, cardiomyopathy, megacolon, megaesophagus β1-adrenergic
β2-adrenergic
M2-muscarin
Tachyarhythmia, atrial ﬁbrillation β1-adrenergic
β2-adrenergic
M2-muscarin
Postural hypotension β2-adrenergic
Complex regional pain syndrome β2-adrenergic
M2-muscarinthat agonistic β1AR autoantibodies could be involved in up to 10% of car-
diacmorbidity inwestern societies. This ﬁgure is probably even higher in
South America, where β1AR autoimmunity is triggered by endemic in-
fection with Trypanosoma cruzi [17]. However, these estimates remain
highly speculative pending the results of an on-going prospective cohort
study on the prevalence of agonistic β1AR autoantibodies in DCM and is-
chemic heart disease [18]. It must ﬁnally be noted that depending on the
detection method deployed agonistic β1AR autoantibodies can be also
determined in up to 12% of healthy individuals [8,19].
From these observations the postulate can be derived that patients,
whose cardiac health is endangered by agonistic β1AR autoantibodies,
should be identiﬁed, monitored and subjected to speciﬁc therapies
counteracting the adverse effects of the autoantibodies on cardiac func-
tion. Various procedures have been developed to protect or cure pa-
tients from the adverse effects of agonistic β1AR autoantibodies either
by removing the antibodies from the blood stream or by neutralising
them in situ by systemic application of synthetic mimics of the epitope
[20–23]. However, a targeted application of these concepts to the causal
therapy or prevention of heart failure is currently hampered by diagnos-
tic issues, as there are no available assays that are suitable for reliable
quantiﬁcation of β1AR autoantibodies in patient's blood samples or a
standardised assessment of their impact on receptor function. There-
fore, it is currently not readily possible to select patients for speciﬁc
antibody-targeted therapies and to monitor such therapeutic regimen
in a clinical setting. Here, we will review the current state of knowledge
regarding these therapeutic and diagnostic aspects of the issue and try
to give an outlook on further developments.
2. The evidence of β1AR-directed autoimmune cardio-pathogenesis
DCM-associated auto-reactive IgG has the potential to stimulate
cAMPproduction [24] andMAP-kinase signalling [25] via theβ1/2AR, in-
hibit cAMP signalling via the M2-muscarinic receptor [26], and exert
negative inotropic effects via Fcγ receptors [27]. These pleiotropic auto-
antibody effects have been discriminated by blockade with selective re-
ceptor antagonists and/or proteins presenting the respective bindingtein coupled receptors.
target Effect on receptor function References
Stimulation [87–89]
endothelin-1 Stimulation [20]
Stimulation [90,91]
, type 1 Stimulation [92]
Stimulation [8,26,28,30,34]
ic acetylcholine
Stimulation [31,33]
ic acetylcholine
Stimulation [16,93–95]
ic acetylcholine
Inhibition [96]
Stimulation [97]
ic acetylcholine
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bodies enhancing the activity of the β1AR are of particular relevance
for the development of DCM in humans [32]. Such autoantibodies are
frequently found in serum of patients with chronic heart failure. Their
prevalence is associated with Chagas' cardiomyopathy [33], DCM [8,
34] or ischemic heart disease [8], but not cardiomyopathies of other
aetiology [15,35,36]. Epitopes most frequently targeted by agonistic
β1AR autoantibodies are located in ﬁrst and second extracellular loops
of the receptor [28,29]. Human autoantibodies directed against these
epitopes exert positive ino- and chronotropic effects on cardiomyocytes
[8,35,37]. Similar effects were demonstrated for antibodies produced in
rodents against peptides corresponding to the second extracellular
β1AR loop, which cross-react with the native β1AR [35,38,39]. More-
over, such immunisations induced left ventricular dilation and dysfunc-
tion [9,10,40] among other effects compatible with chronic cardiac
dysfunction [11–13]. These pathological effects were reversible upon
removal of the antibodies [41], transferable via serum transfusions
[10,13,42,43], and partially abrogated by β1AR antagonists [44] or syn-
thetic mimics of the receptor epitope [45,46]. In DCM patients, preva-
lence [8] and cAMP stimulatory efﬁcacy [24] of β1AR autoantibodies
are correlated to a more reduced cardiac function [8], increased cardiac
mortality [6], more severe ventricular arrhythmia [47], and sudden car-
diac death [48,49]. Therefore, autoimmunity against the second extra-
cellular loop of the β1AR is considered a cause or cofactor of chronic
left ventricular dysfunction and a potential therapeutic target [22,41,
45,46,50–52]. Interleukine-6 seems to promote β1AR directed autoim-
mune cardiomyopathy through enhancing antibody production [53],
but it is not known what initiates the generation of potentially patho-
genic β1AR autoantibodies. Various viral and microbial candidate pro-
teins have been proposed [54] to trigger bystander effects analogous
to the ribosomal P2β protein of T. cruzi, which induces β1AR-directed
autoimmune cardiomyopathy in Chagas' disease [54,55]. However,
ﬁrm evidence of a microbial immunogenic agent that can cause DCM
by raising a β1AR-directed humoral immune response is still lacking.
Therefore, the only speciﬁc causal therapy conceivable to date is the re-
moval or neutralisation of the autoantibodies [20–23,56].
3. Impact of autoantibodies on β1AR conformation and function
3.1. Impact on base line receptor activity
Many β1AR autoantibodies retrieved from patients with DCM or is-
chemic cardiomyopathy are “agonistic” in asmuch as they have the po-
tency to moderately increase cAMP stimulation through the otherwise
un-liganded receptor [24,34,57]. The occurrence of agonistic β1AR auto-
antibodies is a predictive factor of DCM mortality [6], and therefore of
considerable diagnostic interest. Agonistic β1AR autoantibodies appear
to fall into two classes regarding the impact on baseline receptor activ-
ity: About half of the autoantibodies found in DCM or ischemic heart
disease are “high” activators that are almost half as efﬁcient as full ago-
nists such as isoprenaline, whereas the other half are “low” activators
that reach only a third of the effect of the “high” activators. Interestingly,
the effect of “low” activators on cAMP can be preferentially blocked by
peptide homologs of the ﬁrst extracellular loop of the β1AR, while
“high” activators can be preferentially blocked by peptide homologs of
the second extracellular loop of the β1AR, which indicates that the
two classes of agonistic autoantibodies target different portions of the
receptor [24]. It stands to reason that the heterogeneous impact of the
autoantibodies on base line receptor activity is related to an equally het-
erogeneous impact on receptor conformation (see: 3.2), but this has not
yet been systematically investigated.
3.2. Induction of conformational changes in the receptor molecule
The molecular mechanisms by which autoantibodies activate the
β1AR are not yet fully understood. Activation ofβARby agonistic ligandsinvolves a conformational switch enabling Gs-protein coupling [58,59].
It has been proposed that β1AR autoantibodies recognise conformation-
al epitopes [8] prompting the hypothesis that they modulate β1AR con-
formation similar to agonists [57] and/or alter the stability of transient
conformational receptor states that are spontaneously assumed or in-
duced by agonists [32]. More recently, this hypothesis has been proven
using a genetically engineered β1AR bearing a ﬂuorescence resonance
energy transfer (FRET) sensor for the activation-associated conforma-
tion switch. A similar change in FRET-efﬁciency was observed upon
exposure to β1AR autoantibodies as upon exposure to an agonist [37],
demonstrating that the autoantibodies indeed alter the conformation
of the receptor molecule in an agonist-like fashion. However, there is
no clear correlation between the impact of the autoantibodies on recep-
tor conformation (as detected by a FRET sensor) and their impact on
base line receptor activity (as detected by increased cAMP production
in the absence of agonistic ligands), indicating that the autoantibodies
induce and/or stabilise a range of different receptor conformations
that are heterogeneous regarding their efﬁciency of coupling to the
stimulatory G-protein and adenylate cyclase. Interestingly, β1AR auto-
antibodies isolated from DCM patients induce or stabilise receptor con-
formations that are as active as the ones induced by agonists, while
β1AR autoantibodies isolated from healthy individuals mostly induce
changes in receptor conformation not leading to cAMP stimulation
[37]. In summary, these studies corroborate the notion that β1AR auto-
antibodies bind conformational epitopes transiently formed by a small
domain encompassing ﬁrst and second extracellular loops of the recep-
tor. This particular interaction results in stimulation of the receptor to a
varying degree by inducing or stabilising distinct conformations of that
domain.
3.3. Impact on receptor trafﬁcking and maximal agonist response
Heart failure following chronic β1AR stimulation is typically associ-
ated with a reduction of β1AR-mediated regulatory amplitude due to
an increase in baseline cAMP and a decrease in maximal chronotropic
catecholamine response [60]. A similar situation is promoted by β1AR-
autoantibodies present in subpopulations of DCM patients, which in-
crease cAMP baseline while attenuating maximal cAMP response to a
β1AR agonist [57]. This feature appears to be associated with an addi-
tional property of the autoantibodies, namely the attenuation of agonist
induced receptor internalisation. About half of DCM-associated agonis-
tic autoantibodies studied in this respect inhibit receptor trafﬁcking.
As a consequence, maximal catecholamine-induced cAMP production
is differentially affected by agonistic β1AR autoantibodies: Those auto-
antibodies that attenuate receptor internalisation dampenmaximal cat-
echolamine response, while those autoantibodies that have no effect on
receptor trafﬁcking increase maximal isoproterenol response [37]. The
impact on receptor internalisation appears directly linked to the inter-
action of the autoantibodieswith the receptor (as opposed to e.g. the co-
incident action of autoantibodies blocking clathrin), because the effect
can be blocked by pre-adsorptionwith a peptide homolog of the second
extracellular loop domain of the β1AR. Currently it is not clear what de-
termines the distinct impact of agonistic β1AR autoantibodies on recep-
tor trafﬁcking and how this property is related to cardio-pathogenesis.
3.4. A model explaining functional autoantibody effects
Thedata reviewed in this chapter strongly suggest thatβ1AR autoan-
tibodies have heterogeneous effects on baseline activity, maximal ago-
nist response and trafﬁcking of the receptor. These effects are linked
to the ability to bind conformational epitopes presented by a domain
encompassing the ﬁrst and second extracellular loops of the β1AR. It re-
mains unclear how the impact on receptor conformation is mechanisti-
cally linked to the effect on receptor activity, since the receptor domain
targeted by the autoantibodies is not identical and not even close to the
ligand binding-site, as predicted from high resolution X-ray diffraction
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based on the aforementioned structural data, one can assume that the
receptor domain targeted by the autoantibodies presents one series of
transient conformations when the receptor idles and another slightly
different series of transient conformationswhen it undergoes activation
by an agonist. Individual cocktails of β1AR autoantibodies present in
patients or healthy individuals will bind and stabilise distinct subsets
of these conformations, thereby “freezing” the receptor in a unique
transient state of activity/inactivity, and thus exerting a unique impact
on its function, which provides a plausible explanation for the inter-
individual heterogeneity of the impact ofβ1AR autoantibodies on recep-
tor functions. In general, β1AR autoantibodies present in the circulation
of patients with chronic heart failure (CHF) appear to have higher
levels/avidities and stimulate and/or sensitise the receptor (i.e. target
conformational epitopes presented both by inactive receptors, which
are then switched into an active conformation, and by active receptors,
which are further stabilised). In contrast, β1AR autoantibodies present
in the circulation of healthy individuals have lower levels/avidities and
no signiﬁcant effects on β1AR activity (i.e. target conformational epi-
topes not relevant for receptor activity/activation). Some autoanti-
bodies even act as mild antagonists (i.e. target epitopes not altering
conformation during receptor activation/inactivation). Thus, it is not
the mere presence of β1AR autoantibodies that distinguishes DCM pa-
tients fromhealthy subjects, but a different impact of the autoantibodies
on β1AR functionmost likely dependent on/related to the conformation
of the targeted epitope. This fact needs to be taken into consideration
when devising therapeutic and diagnostic strategies.
4. Mechanism of cardio-noxicity of β1AR autoantibodies
It is to be expected that the continuous exposure to agonistic β1AR
autoantibodies leads to desensitisation and ultimately down-regulation
of cardiacβ1AR [62],which is a commonhallmark of CHF [60,63]. Rodents
undergoing left ventricular dysfunction following immunisation with
synthetic homologs of the second extracellular loop of the β1AR have
indeed reproducibly shown alterations of cardiac signal transduction
compatible with this putative pathogenic mechanism [9–11,64]. Howev-
er, in vitro-exposures of cardiomyocytes or other cellular reporter sys-
tems of β1-adrenergic signal transduction to agonistic β1AR
autoantibodies derived from human DCMpatients have failed to induce
receptor desensitisation or gradual attenuation of cAMP-accumulation
over time [34], whichmay be connected to the potency of the autoanti-
bodies to inhibit agonist-induced receptor internalisation [37]. There-
fore, it cannot be excluded that mechanisms other than
desensitisation of cardiac β1AR mediate the cardio-noxicity of the anti-
bodies. It has been observed that agonistic β1AR autoantibodies stimu-
late apoptosis [13,65] and stress responses of the endoplasmic
reticulum [42], suggesting that the pathogenic mechanismmay involve
direct cardiac cytotoxicity. Moreover, it has been shown that the auto-
antibodies induceMAP-kinase and β-arrestin signalling [25], which po-
tentially interfere with β1-adrenergic signal transduction [66].
Furthermore, DCM-derived β1AR autoantibodies alter the function of
cardiac L-type Ca2+ channels [38,67] and are suspected tomodulate lat-
eral mobility of the receptors through simultaneous interactions with
Fcγ receptor IIa recently discovered on cardiomyocytes [27]. Finally it
has been suggested that the antibodies induce homo-dimerisation of
β1AR [3], which is known to play a role in cardiac signalling efﬁcacy
and contractility [68,69]. In summary, receptor desensitisation seems
to be the major cardio-pathogenic mechanism of β1AR autoimmunity
in immunised rodents, while cardio-noxicity of agonistic β1AR autoan-
tibodies in humans could also be executed by a variety of other mecha-
nisms. However, this discrepancy does not impinge on the principle
desideratum that the primary interaction between receptor and ago-
nistic autoantibody should be addressed by diagnostic and therapeu-
tic measures, irrespective of the cardio-noxious mechanisms
downstream thereof.5. Therapeutic approaches
5.1. Removal of autoantibodies by extracorporeal absorption
Numerous studies on the treatment of DCM by non-selective im-
mune apheresis (IA) of circulating IgG or selective extracorporeal re-
moval of the IgG3 subclass have largely shown positive effects on
haemo-dynamics, NYHA classiﬁcation of disease state, hospitalisation,
bio-markers of cardiac function and other clinical parameters of disease
activity (reviewed in: [20,21]). Interestingly, two small uncontrolled
pilot studies using immobilised peptide homologs of the β1AR epitope
for selective IA have provided similarly positive results [52,70], which
suggests that among a multitude of cardiac autoantibodies potentially
involved in the pathogenesis of DCM [71,72] β1AR autoantibodies ap-
pear to play a paramount role. Due to the very small case series of the
two studies on β1AR-selective IA (n = 8) and the heterogeneity of
follow-up parameters, the therapeutic efﬁcacy of β1AR-selective and
unselective IA cannot be compared based on existing data, and it re-
mains to be evaluated, whether selective IA has a signiﬁcant clinical
beneﬁt over the more ﬁrmly established non-selective IA protocols. It
is also conceivable that new synthetic mimics of one or several autoan-
tibody epitope(s) (see 5.2) can be employed to further improve the per-
formance of selective IA. However, irrespective of the IA procedure
utilised, DCM patients apparently proﬁt most from it when β1AR auto-
antibodies are present at baseline [20], which is in line with the obser-
vation that the presence of agonistic β1AR autoantibodies at baseline
predicts DCM morbidity and cardiovascular mortality [6,8,24,47–49].
In summary, IA is a valid and largely established therapy option for
DCM, provided it is possible to select the subgroup of DCM patients
that are positive for agonistic β1AR autoantibodies, and to monitor
clearance and reappearance or persistence of the autoantibodies during
follow-up.
5.2. Systemic neutralisation of autoantibodies
Two approaches have been established to neutralise β1AR autoanti-
bodies by the systemic application of ligands that mimic the targeted
epitope. One type of such synthetic neutralising ligands has been
made by afﬁnity selection and single step exponential enrichment of a
short single-stranded nucleotide sequence (aptamere) [73] that binds
with high afﬁnity to the epitope recognition site ofβ1AR autoantibodies.
It has been shown that this aptamere can neutralise the ino- and
chronotropic effects of DCM-derived β1AR autoantibodies on neonatal
rat cardiomyocytes in vitro [45] and decrease the levels of agonistic
β1AR autoantibodies in spontaneously hypertensive rats [74]. It remains
to be demonstratedwhether this compound is also able to reverse dilat-
ed cardiomyopathy in an immunisationmodel and, thus, may be suited
for the further development of a systemic therapy in human heart
failure [75].
The other approach consists in a peptide-based strategy aiming to
speciﬁcally neutralise conformational β1AR autoantibodies directly in
the circulating blood to prevent their harmful cardio-stimulatory effects.
To this end, peptide-homologsmimicking the epitope(s) thought to rep-
resent the key target of agonistic β1AR antibodies, that is, the second
extra-cellularβ1AR loopwere generated and cyclised in order to increase
their stability in vivo. These peptides are referred to as β1ECII-CP or COR-
1. In pre-clinical studies β1AR antibody-positive sera from immunised
rats served to assess the blocking capacity of β1ECII-CP both in vitro
and in vivo [22]. In vitro pre-incubation of stimulating rat β1AR antibod-
ies with β1ECII-CP efﬁciently blocked receptor signalling and reduced
β1AR antibody-induced cAMP-production by more than 80%. Similarly,
injection of β1ECII-CP into immunised rats resulted in a signiﬁcant
antibody-neutralising effect in vivo, and reduced the initially observed
cAMP-response by about 60% (assays performed before and 24 h after
β1ECII-CP injection) [49]. In addition, long-term injection of β1ECII-CP
(every 4 weeks over 12 months) was found to revert cardiac dilatation
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cardiomyopathic rats [76], indicating that β1ECII-CP might be beneﬁcial
also in the treatment of agonistic β1AR autoantibody-positive human
heart failure. Recently, the ﬁrst application of β1ECII-CP in man has
been successfully accomplished [46], and a clinical phase IIa trial with
this compound is currently under way.
Neutralisation of β1AR autoantibodies by systemic application of
synthetic epitope mimics could evolve into a more versatile, less inva-
sive, less expensive and less hospitalisation-burdened alternative. How-
ever, like IA, this therapy option will require the selection of suitable
DCM patients (that are positive for agonistic β1AR autoantibodies) and
a monitoring of the levels of the circulating autoantibodies β1AR during
therapy and follow up. Therefore, it will be necessary to move the as-
sessment of β1AR autoantibodies from research to clinical diagnostics
in order to develop suitable assays for agonistic β1AR autoantibodies
that meet the requirements of standardisation and reliability of clinical
diagnostic tests.6. Diagnostic issues
6.1. The problem of the polymorphic and labile native autoantibody-epitope
The receptor domain targeted by β1AR autoantibodies associated
with DCM and other cardiac diseases encompasses the ﬁrst and second
extracellular loops of the receptor [28,29], which are the only extracel-
lular domains capable of inducing the production of antibodies exerting
pharmacological effects on the receptor [77]. The three-dimensional
structure of this domain as predicted from high resolution X-ray diffrac-
tion data of the human β2AR [58,59] and the turkey β1AR [61] is an ex-
tracellularα-helix formed by the second extracellular loop. This helix is
linked via an S–S bridge to themore amorphous structure of theﬁrst ex-
tracellular loop. There is a strong argument that the entire domain
changes its conformation during receptor activation/inactivation and
in doing so presents a multitude of transient conformational epitopes,
which are targeted by β1AR autoantibodies (see 3.2 and 3.4). As a con-
sequence, the autoantibodies poorly cross-react with linear representa-
tions or denatured versions of the targeted receptor domain. In linewith
that notion, DCM-associated β1AR autoantibodies are unable to bind to
denatured human β1AR presented on Western-blots, unless the blots
are ﬁrst subjected to extensive renaturation procedures [8]. Moreover,
the binding of human autoantibodies to native β1AR presented on the
surface of overexpressing cells is rapidly destroyed by all known ﬁxa-
tion procedures (Fig. 1), supporting the notion that the antibodies
indeed target an extremely labile conformational epitope [37]. Along
the same lines, detection of β1AR autoantibodies by their binding to
immobilised peptide homologs of the target domain is poorly correlated50% MAcetonenative
Fig. 1. Disruption of IgG co-localisation with native bioﬂuorescent β1ARs by cell ﬁxation. Rece
microscopy at 400-fold magniﬁcation in cells overexpressing YFP-fused human β1ARs and stai
immune IgG, the cells were exposed (for 5 min at 4 °C) to PBS (left), 100% acetone (middle left)
the author's permission from [37].with the results of immunoassays based on native β1AR presented on
intact cells [8]. It appears that peptide-based immunoassays are much
less sensitive and speciﬁc than cell-based assays and only detect a sub-
set of positive patients [37]. This probably explains, why studies on the
prevalence of β1AR autoantibodies in cardiac diseases have largely
diverging results. In general, much higher ﬁgures are reported using
peptide-based immunoassays [49,78] as compared to native cell-based
assays [8,15,24]. The discrepancy is currently blamed on a high rate of
false positive results. Clinical correlations suggest that the ﬁgures de-
rived from native cell-based assays are more valid. As a consequence,
peptide-based immunoassays are currently not considered a valid tool
for the detection of clinically relevant human β1AR autoantibodies [5,
32], and assays based on native (living) cells are still the main stay of
clinical and pre-clinical studies [3,18,31,45,74]. However, the latter as-
says are clearly unsuited for routine clinical diagnostics.6.2. Routine assays for the detection of β1AR autoantibodies
In principle there are three routes available that possibly lead to the
development of standardised and valid routine assays for the detection
of potentially cardio-pathogenic β1AR autoantibodies in human blood
samples.
One approach is to replace in solid phase immunoassays the linear
peptide homologswith improved syntheticmimics of the target domain
such as aptameres [3] or cyclic peptides (e.g. the COR-1 peptide [46]). To
our knowledge this has not been thoroughly worked out/optimised or
the so far obtained results were not satisfying.
As a second approach, native cell-based assays could be reformulated
in such a way that they can be subjected to normal storage and transport
procedures and meet the requirements of standardisation and quality
control in routine clinical diagnostics. One step in that direction is the re-
cent development of a competition ELISA based on formaldehyde-ﬁxed
cells overexpressing the humanβ1AR and a competitivemonoclonal anti-
body against the autoantibody target domain that speciﬁcally displaces
human autoantibodies bound to that site. The assay was validated ac-
cording to “good laboratory practice” and can serve as a companion
bio-diagnostic assay for the development and evaluation of antibody-
directed therapies in antibody-positive heart failure [39]. However, it
remains to be seen whether this approach is suitable for the sensitive
detection of β1AR autoantibodies in a broad range of human blood sam-
ples, given the limitations imposed on the sensitivity by cell ﬁxation and
the competing monoclonal antibody, which both reduce the scope of
conformational epitopes represented by that assay. Another possible
starting point is the determination of autoantibody binding to native
cells overexpressing bioﬂuorescent β1AR bymeans of quantitative ﬂuo-
rescence microscopy or ﬂuorescence-activated ﬂow cytometry. These2% FAeOH
β1 AR-YFP
bound IgG
ptor- (top) and IgG-associated ﬂuorescence (bottom) visualised by confocal ﬂuorescence
ned with human autoimmune IgG from a DCM patient. Prior to the incubation with auto-
, 50%methanol in PBS (middle right), or 2% formaldehyde in PBS (right). Image citedwith
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β1AR autoantibodies fromDCMpatients and healthy subjects in a quan-
titativemanner [37] and could be further developed into a clinical test if
the problems of storage and transport can be solved. Digital ﬂuores-
cence microscopy with modern pattern recognition algorithms could
be a promising option for standardisation of such native cell-based as-
says in a clinical setting [79,80].
A third approach could be to produce semi-synthetic targets for the
autoantibodies that consist of native β1ARs solubilised from the cell
membranes and reconstituted in synthetic lipid vesicles. Such procedures
have been developed and successfully used for the functional reconstitu-
tion of β1-adrenergic signal transduction from puriﬁed components [81].
β1AR thus reconstituted in their native conformation are known to
remain fully functional upon prolonged storage at−20 °C and therefore
could be used in immune assays as a durable test antigen that presents
the full scope of native conformational epitopes targeted by β1AR
autoantibodies.
It should ﬁnally be noted that there remains an unsolvable problem
of standardisation and validation that applies to all three approaches.
The analyte (that is, the β1AR autoantibody) represents a heteroge-
neous mixture with respect to the target epitope. Therefore it will be
almost impossible to formulate standards and calibrators that are repre-
sentative of the entirety of β1AR autoantibody variants occurring in pa-
tients (and probably also in some healthy subjects). As a consequence,
the performance of all these approaches can only be validated by clinical
correlation of the prevalence of test results in blood samples of con-
trolled study cohorts (e.g. the ETiCS study [18]). This may eventually
pose a problem for the certiﬁcation and accreditation of these diagnostic
tools for an application in routine health care.
6.3. Discrimination of stimulating and non-stimulating β1AR autoantibodies
DCM patients and healthy subjects are not discriminated by the
mere presence of β1AR autoantibodies, but by a different impact of
their autoantibodies on β1AR function (see chapter 3). Only the preva-
lence of agonistic β1AR autoantibodies is clearly correlated with in-
creased morbidity and mortality in DCM [6]. Therefore the mere
demonstration of β1AR-binding IgG in the blood of a patient or healthy
individual does not provide a sufﬁcient basis for diagnostic predictions
or therapeutic decisions. It needs to be discriminatedwhether the auto-
antibodies stimulate the receptor or not. Currently this distinction is
often based on the impact of the puriﬁed IgG fraction on beating rate
and contractility of spontaneously beating cardiomyocytes isolated
from neonatal rats [82]. Alternatively, this assay can be performed
with spontaneously beating human embryonic cardiomyocytes gener-
ated by in vitro differentiation from induced human adult stem cells
[37]. Both bio-assays are not suited for clinical diagnostics because
they are constituted of primary cells that must be freshly prepared
each time the assay is to be performed.Moreover, the readout is difﬁcult
to standardise even when employing automated monitoring of cell im-
pedance [83]. An alternative more suited to routine clinical application
are engineered cellular reporter systems of β1-adrenergic signal trans-
duction that are based on immortalised cells. The most elegant of these
assays is a cell line overexpressing human β1AR in the cellmembrane to-
gether with a cytosolic FRET-reporter of cAMP concentration. This sys-
tem has already been evaluated in a large cohort of patients. It enables
a clear distinction of agonistic and non-stimulating β1AR autoantibodies
and even discriminates between strong and weak agonistic β1AR auto-
antibodies [24]. From the point of view of availability of analytical plat-
forms, it would be more convenient to combine β1AR overexpression
with a light-generating cAMP-reporter gene assay. Such systems have
been successfully established for various GPCRs [1,84–86] and are cur-
rently FDA-approved for clinical diagnostics of TSH-R autoantibodies in
Grave's disease [1]. In principle it is conceivable to engineer even more
versatile semisynthetic reporter assays by reconstitution of puriﬁed
components in lipid vesicles [81].7. Conclusions
By now, conformational agonistic β1AR autoantibodies are clearly
recognised as playing a pivotal role in human heart failure, either as a
disease-causing agent or as a “negative” disease-modiﬁer. Preliminary
clinical data clearly suggest that the presence of agonistic β1AR autoan-
tibodies signiﬁcantly worsens the prognosis of patients suffering from
idiopathic DCM. A broader and more complete picture of pathophys-
iologic and prognostic issues in β1AR autoantibody-mediated heart
disease will emerge from the result of prospective diagnostic studies
currently planned or under way (e.g. the ETiCS-study), which are ex-
pected to provide new insights into cardiac events capable of triggering
β1AR-directed autoimmune processes and the contribution of such pro-
cesses to the initiation and/or progression of CHF. In particular, we
might learn and better understand whether – and if so, then to which
extent – the speciﬁc target epitope(s) of a conformational β1AR autoan-
tibody, but also its respective titre and biological activity, and its respec-
tive kinetics (that is, antibody-persistence or -clearance over time)
relate to the complex process of cardiac remodelling and dilation (and
its eventual reversal). Different β1AR autoantibodies might have dis-
tinct propensities to induce a certain cardiac phenotype, and studies
such as ETHiCS will allow for a differentiation of such features in a pro-
spective manner.
Already there exist a variety of speciﬁc therapy options for β1AR
autoantibody-mediated heart disease. These include non-selective IA
of total IgG and selective IA of IgG3, which are largely established thera-
py options, and selective IA of β1AR autoantibodies, which may have
some advantages over the other IA options pending corroborative clin-
ical studies of larger case series. An alternative to IA that is potentially
more versatile, less invasive, less expensive and less burdened with
hospitalisation is the neutralisation and clearance of β1AR autoanti-
bodies by systemic application of synthetic epitope mimics. However,
preclinical evaluation of such concepts has not yet been completed. A
roll out of any of these therapeutic approaches into routine health
care will eventually require (i) the selection of patients likely to proﬁt
from the therapy because they are positive for agonistic β1AR autoanti-
bodies and (ii) a monitoring of the circulating levels of these autoanti-
bodies during therapy and follow up.
The assays currently in use for the detection of β1AR autoantibodies
and the determination of their impact on receptor function are unﬁt for
routine health care, because they employ primary cardiomyocytes or
cell lines overexpressing the target receptor. The readout of such live
cell reporter systems is difﬁcult to standardise— evenwhen automated.
It poses a major challenge for future development to move the assess-
ment of circulating agonistic β1AR autoantibodies from research proce-
dures to clinical diagnostics, and to develop assays that accomplish the
requirements of standardisation and reliability of clinical diagnostic
testing. While developing such diagnostic tests one needs to keep in
mind that the assays must (i) detect autoantibodies recognising a con-
formational epitope so far only found properly represented in the native
β1AR, and (ii) discriminate autoantibodies that bind and stimulate the
β1AR from autoantibodies that bind the β1ARwithout affecting its func-
tion. Possibly, that dual diagnostic goal will be best reached by a staged
strategy. It is the ﬁrm belief of the authors that valid, standardised diag-
nostic tests for agonisticβ1AR autoantibodieswill substantially promote
further development and evaluation of personalised therapeutic strate-
gies speciﬁcally directed at clearance or neutralisation of distinct β1AR-
autoantibody species that prove to be cardio-noxious in a given patient
or disease-entity.Conﬂict of interest
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960 B. Bornholz et al. / Autoimmunity Reviews 13 (2014) 954–962Take-home messages
• Conformational agonistic β1AR autoantibodies play a pivotal role in
human heart failure.
• Speciﬁc therapy options already exist for heart disease mediated by
these autoantibodies.
• Roll out of these therapeutic approaches into routine health care will
require (i) the selection of patients positive for agonistic β1AR autoan-
tibodies and (ii) the monitoring of circulating autoantibody levels
during therapy and follow up.
• However, valid assays currently available for the detection of agonistic
β1AR autoantibodies are unﬁt for routine health care, as they are
based on live cell models.
• It poses a major challenge for future development to develop assays
that (i) detect autoantibodies recognising a conformational epitope
so far only foundproperly represented in the nativeβ1AR, (ii) discrim-
inate autoantibodies that bind and stimulate the β1AR from autoanti-
bodies that bind the β1AR without affecting its function, and (iii)
accomplish the requirements of standardisation and reliability of clin-
ical diagnostic testing.
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